Patheon Inc

Patheon — Q1 2006 Earnings Presentation

10 slides from Patheon's earnings presentation, Mar 3, 2006

  1. Slide 1: Q1 2006 Financial Results Conference Call

    Q1 2006 FINANCIAL RESULTS CONFERENCE CALL March 3, 2006 10:00 a.m. (EST) Forward-looking Information This presentation contains forward-looking statements, which reflect management’s expectations regarding the Company’s future growth, results of operations, performance (both operat ional and financi

  2. Slide 2: Presenting on Behalf of Patheon / Agenda

    Presenting on Behalf of Patheon Robert Tedford Chief Executive Officer Nick DiPietro President and Chief Operating Officer Rodger Roden Chief Financial Officer and Senior Vice-President, Finance Agenda Opening comments/strategic highlights (R. Tedford) Q1 2006 financial results (R. Roden) Revi

  3. Slide 3: Overview of the Quarter

    Overview of the Quarter  A challenging quarter Greater-than-expected impact of Omnicef® Deferred orders to later quarters at Monza Production issues at Swindon, Whitby Lower OTC volumes Canadian PDS growth constrained primarily by capacity issues at TRO  Revising outlook for the full year  I

  4. Slide 4: Q1 2006 Financial Highlights

    Q1 2006 Financial Highlights  Revenues up 3% to $157.9M Rx, PDS up 5%, OTC down 10% Europe up 12% (23% on CER basis), NA down 1%  EBITDA margin of 8.9% vs. 14.1% EBITDA of $14.0M vs. $21.6M  Excluding impact of one-time costs, loss of 5.8¢ per share  Net loss of $11.5M, or 12.4¢ per share, vs

  5. Slide 5: Depreciation, Amortization, Interest; Earnings (Loss)

    Depreciation, Amortization, Interest Q1 2006  Depreciation and amortization expense increase of $2.0M  Amortization of intangibles increase of $2.1M  Interest expense increase of $2.8M  Increases reflects inclusion of a full quarter of expenses relating to the MOVA acquisition vs. five weeks in

  6. Slide 6: Cash Provided by Operating Activities

    Cash Provided by Operating Activities Q1 2006  Cash provided from operations of $7.8M vs. $20.5M a year ago  Additions to capital assets of $13.9M vs. $13.5M a year ago Establishment of lyo ceph capability at Swindon Establishment of high-potency at Bourgoin-Jallieu  Consolidated interest-beari

  7. Slide 7: Q1 Revenue Growth

    Q1 Revenue Growth Europe  European revenues grew $5.2M or 12% ($9.8M or 23% on CER basis) Rx revenues up 13% Improved volumes at Swindon Continuing strong demand for lyo services in Italy Revenues from carve-outs in Italy, France PDS revenues up 14% Solid base of business at Swindon  Europea

  8. Slide 8: Outlook: Continued growth in PDS Projects

    Continued growth in PDS Projects Preclinical Preclinical Phase I Phase Phase IIII Phase Phase III III NDA NDA Total Q1-06 23 37 58 28 6 152 Y/E-05 20 38 53 30 6 147 Y/E-01 5 8 11 11 5 40 15 product launches since 2001, Including one in Q1 2006 OUTLOOK Q1 2006 Webcast Presentation 8

  9. Slide 9: Outlook

    Outlook We continue to expect 2006 to be challenging, with stronger performance in second half Expecting full-year EBITDA and net earnings to be lower than fiscal 2005 operating challenges in Q1 greater-than-anticipated declines in base business Improved results in Q2, further improvement in se

  10. Slide 10: A New Era

    A NEW ERA Q1 2006 Webcast Presentation 10

Patheon — Q1 2006 Earnings Presentation on 6ix